200 related articles for article (PubMed ID: 26671986)
41. Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.
Miller JJ; Shih HA; Andronesi OC; Cahill DP
Cancer; 2017 Dec; 123(23):4535-4546. PubMed ID: 28980701
[TBL] [Abstract][Full Text] [Related]
42. Diffuse gliomas in patients aged 55 years or over: A suggestion for IDH mutation testing.
Barresi V; Eccher A; Simbolo M; Cappellini R; Ricciardi GK; Calabria F; Cancedda M; Mazzarotto R; Bonetti B; Pinna G; Sala F; Ghimenton C; Scarpa A
Neuropathology; 2020 Feb; 40(1):68-74. PubMed ID: 31758617
[TBL] [Abstract][Full Text] [Related]
43. Development of a Rapid and Sensitive IDH1/2 Mutation Detection Method for Glial Tumors and a Comparative Mutation Analysis of 236 Glial Tumor Samples.
Avsar T; Sursal A; Turan G; Yigit BN; Altunsu D; Cantasir K; Duyu G; Bayoumi AB; Yapicier O; Acar M; Kilic T
Mol Diagn Ther; 2020 Jun; 24(3):327-338. PubMed ID: 32274701
[TBL] [Abstract][Full Text] [Related]
44. New IDH1 I113T mutation associated with BRAF V600E mutation: new driver of gliomagenesis?
Tabouret E; Fina F; Vincentelli F; Nanni I; Figarella-Branger D
J Neurol Sci; 2014 Jul; 342(1-2):204-6. PubMed ID: 24857351
[TBL] [Abstract][Full Text] [Related]
45. Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma.
Chen L; Voronovich Z; Clark K; Hands I; Mannas J; Walsh M; Nikiforova MN; Durbin EB; Weiss H; Horbinski C
Neuro Oncol; 2014 Nov; 16(11):1478-83. PubMed ID: 24860178
[TBL] [Abstract][Full Text] [Related]
46. IDH1 status is significantly different between high-grade thalamic and superficial gliomas.
Zuo M; Li M; Chen N; Yu T; Kong B; Liang R; Wang X; Mao Q; Liu Y
Cancer Biomark; 2017 Aug; 20(2):183-189. PubMed ID: 28869450
[TBL] [Abstract][Full Text] [Related]
47. Sequencing IDH1/2 glioma mutation hotspots in gliomas and malignant peripheral nerve sheath tumors.
Håvik AB; Lind GE; Honne H; Meling TR; Scheie D; Hall KS; van den Berg E; Mertens F; Picci P; Lothe RA; Heim S; Brandal P
Neuro Oncol; 2014 Jan; 16(2):320-2. PubMed ID: 24311631
[No Abstract] [Full Text] [Related]
48. Analysis of isocitrate dehydrogenase 1 mutation in 97 patients with glioma.
Zhou YX; Wang JX; Feng M; Sun CM; Sun T; Chen GL; Du ZW
J Mol Neurosci; 2012 Jul; 47(3):442-7. PubMed ID: 22113362
[TBL] [Abstract][Full Text] [Related]
49. A juvenile case of epilepsy-associated, isocitrate dehydrogenase wild-type/histone 3 wild-type diffuse glioma with a rare BRAF
Sadashima S; Suzuki SO; Haruyama H; Mukae N; Fujioka Y; Hata N; Mizoguchi M; Ishimatsu K; Hiwatashi A; Iwaki T
Neuropathology; 2020 Dec; 40(6):646-650. PubMed ID: 32996219
[TBL] [Abstract][Full Text] [Related]
50. Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas.
Zhang J; Yang JH; Quan J; Kang X; Wang HJ; Dai PG
Tumour Biol; 2016 Oct; 37(10):13571-13579. PubMed ID: 27468718
[TBL] [Abstract][Full Text] [Related]
51. Molecular investigation of isocitrate dehydrogenase gene (IDH) mutations in gliomas: first report of IDH2 mutations in Indian patients.
Das BR; Tangri R; Ahmad F; Roy A; Patole K
Asian Pac J Cancer Prev; 2013; 14(12):7261-4. PubMed ID: 24460285
[TBL] [Abstract][Full Text] [Related]
52. IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors.
Mellai M; Piazzi A; Caldera V; Monzeglio O; Cassoni P; Valente G; Schiffer D
J Neurooncol; 2011 Nov; 105(2):345-57. PubMed ID: 21643842
[TBL] [Abstract][Full Text] [Related]
53. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
[TBL] [Abstract][Full Text] [Related]
54. Molecular analysis of diffuse intrinsic brainstem gliomas in adults.
Reyes-Botero G; Giry M; Mokhtari K; Labussière M; Idbaih A; Delattre JY; Laigle-Donadey F; Sanson M
J Neurooncol; 2014 Jan; 116(2):405-11. PubMed ID: 24242757
[TBL] [Abstract][Full Text] [Related]
55. Gliomas in children and adolescents: investigation of molecular alterations with a potential prognostic and therapeutic impact.
Cabral de Carvalho Corrêa D; Tesser-Gamba F; Dias Oliveira I; Saba da Silva N; Capellano AM; de Seixas Alves MT; Dastoli PA; Cavalheiro S; Caminada de Toledo SR
J Cancer Res Clin Oncol; 2022 Jan; 148(1):107-119. PubMed ID: 34626238
[TBL] [Abstract][Full Text] [Related]
56. Gliomas molecular markers: importance in treatment, prognosis and applicability in brazilian health system.
Soldatelli JS; Oliveira IM; Kneubil MC; Henriques JAP
An Acad Bras Cienc; 2022; 94(3):e20211075. PubMed ID: 35766600
[TBL] [Abstract][Full Text] [Related]
57. Cerebellar glioblastoma: a clinical series with contemporary molecular analysis.
Hong B; Banan R; Christians A; Nakamura M; Lalk M; Lehmann U; Hartmann C; Krauss JK
Acta Neurochir (Wien); 2018 Nov; 160(11):2237-2248. PubMed ID: 30203362
[TBL] [Abstract][Full Text] [Related]
58. Granular cell astrocytoma: an aggressive IDH-wildtype diffuse glioma with molecular genetic features of primary glioblastoma.
Vizcaino MA; Palsgrove DN; Yuan M; Giannini C; Cabrera-Aldana EE; Pallavajjala A; Burger PC; Rodriguez FJ
Brain Pathol; 2019 Mar; 29(2):193-204. PubMed ID: 30222900
[TBL] [Abstract][Full Text] [Related]
59. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.
Sanson M; Marie Y; Paris S; Idbaih A; Laffaire J; Ducray F; El Hallani S; Boisselier B; Mokhtari K; Hoang-Xuan K; Delattre JY
J Clin Oncol; 2009 Sep; 27(25):4150-4. PubMed ID: 19636000
[TBL] [Abstract][Full Text] [Related]
60. Establishing a Robust Molecular Taxonomy for Diffuse Gliomas of Adulthood.
Huse JT
Surg Pathol Clin; 2016 Sep; 9(3):379-90. PubMed ID: 27523967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]